Prostate cancer (PC) is a type of cancer that affects the prostate gland of the male reproductive system, and is the most common non-cutaneous malignant cancer in men. Internationally, it is the sixth-largest cancer-related cause of death in men. Those aged over 50 are at the greatest risk of developing PC, with advanced age being the primary risk factor for the disease.
Most cases of PC (95%) are classed as adenocarcinomas, a type of cancer that arises in the cells of glands. Around 4% of cases display transitional cell morphology, and originate from the urothelial lining of the prostatic urethra. In rare cases prostate cancer may present with neuroendocrine morphology, and can arise from neuroendocrine stem cells present in the prostate. PC begins with the conversion of normal semen-secreting prostate gland cells into cancerous cells. In 75% of cases these start developing in the peripheral zone of the prostate – the site closest to the rectum.
PC is often asymptomatic, which can lead to a lack of diagnosis in the early stages of the disease, rendering treatment less effective once a diagnosis is made. If symptoms are present or if a diagnosis has been made during a physician’s examination, depending on the stage of the disease, the cancer may be treated through surgical removal of cancerous cells, radiation therapy, or a combination of both.
The PC market consists of therapies for both hormone-sensitive and castration-resistant forms of the disease. The options available for the two forms are notably different, with hormonal therapies used in the hormone-sensitive stage, and chemotherapy or targeted therapies used in the castration-resistant stage. Castration-resistant PC relates to both symptomatic and asymptomatic forms of the disease that no longer respond to hormonal therapy.
Hormonal therapies are widely used across multiple stages of hormone-sensitive disease, and the goal is to halt PC growth stimulated by testosterone. There are two methods used to treat PC through targeting hormones. The first is androgen deprivation therapy (ADT) using gonadotropin releasing hormone (GnRH) agonists and antagonists, and the second is androgen receptor (AR) blockage, using compounds termed anti-androgens.
The differences between many of these products are relatively nuanced, and must be understood fully by companies seeking to position a novel drug in this market. This tabular heatmap framework, designed to provide an easily digestible Summary of these clinical characteristics, provides detailed information on all late-stage clinical trial results for products in the PC market and late-stage pipeline. These are split along lines of therapy, and are therefore reflective of the treatment algorithm.
All safety and efficacy endpoints reported in these trials are displayed, for both the drug and comparison groups. In addition, key study characteristics such as the size, composition and patient segment of the study population are provided. These results are presented in a visually accessible, color-coded manner in order to maximize ease of use.
The accompanying text provides a detailed analysis of the clinical benchmarks set by the current market landscape, and the anticipated changes to these benchmarks, and to the treatment algorithm, as a result of the late-stage pipeline.
- What are the clinical characteristics of currently approved therapies for PC, in terms of specific safety and efficacy parameters? - What are the key unmet needs in this indication, and which clinical safety and efficacy parameters are most closely linked to them? - Which novel classes of therapy are expected to emerge in the treatment of PC? - Which targets do these therapies act upon? - Which sub-types of patients could potentially benefit from these new products?
Reasons to buy
- Understand the current clinical landscape by considering the treatment options available for each patient segment. - Visually compare the currently approved treatments available at each line of therapy, based on the most important efficacy and safety parameters tested in clinical trials. - Assess the current late-stage pipeline, in terms of the likely positioning of each product and the implications for the clinical landscape at each line of therapy. - Understand the relative strengths and weaknesses of the studies used to gather these data. - Build up a nuanced understanding of the clinical benchmarks set by these products, and consider how the current late-stage pipeline will affect these benchmarks. - Assess your own pipeline programs in light of these benchmarks in order to optimally position them and maximize uptake by clinicians.
Our reports have been used by over 10K customers, including:
214 pages •
By Asia Market Information & Development Company
• Sep 2020
China’s demand for Anti-Tumor Drugs has grown at a fast pace in the past decade. In the next decade, both production and demand will continue to grow. The Chinese economy maintains a high speed growth which has been stimulated by the consecutive increases of industrial output, imports & exports, consumer consumption...
The North America transdermal drug delivery system market is expected to reach US$ 3,430.81 million by 2027 from US$ 2,422.34 million in 2019; it is estimated to grow at a CAGR of 4.6%from 2020 to 2027. The growth of the market in North America is attributed to increasing prevalence of chronic diseases, growing demand for noninvasive drug...
Women Infertility - Pipeline Review, H2 2020 Summary This latest Pharmaceutical and Healthcare disease pipeline guide Women Infertility - Pipeline Review, H2 2020, provides an overview of the Women Infertility (Women’s Health) pipeline landscape. Infertility refers to failure to conceive over...
Acromegaly - Pipeline Review, H2 2020 Summary This latest Pharmaceutical and Healthcare disease pipeline guide Acromegaly - Pipeline Review, H2 2020, provides an overview of the Acromegaly (Hormonal Disorders) pipeline landscape. Acromegaly is a hormonal disorder that develops when pituitary...
5-Hydroxytryptamine Receptor 7 - Pipeline Review, H2 2020 Summary 5-Hydroxytryptamine Receptor 7 (5 HT7 or 5 HTX or Serotonin Receptor 7 or HTR7) pipeline Target constitutes close to 13 molecules. Out of which approximately 12 molecules are developed by companies and remaining by the universities/institutes....
Hyponatremia Disease - Global Clinical Trials Review, H2, 2020 Summary clinical trial report, “Hyponatremia Disease - Global Clinical Trials Review, H2, 2020" provides an overview of Hyponatremia Clinical trials scenario.This report provides top line data relating to the clinical trials on Hyponatremia. Report...